CRISPR’s Clinical Leap: Strengthening Risk and Audit Practices

The approval of Casgevy, the first CRISPR-based therapy, symbolized a transformative shift from theoretical promise to clinical reality, offering hope to patients who suffer from sickle-cell disease and beta thalassaemia, conditions which stem from genetic disorders.

For Heads of Risk, Compliance, and Audit, this innovation called not only celebration, but also highlighted the need for a revised approach to managing novel risks and complexities.

A new era brings new risks

Casgevy’s groundbreaking application in treating sickle-cell disease and beta-thalassemia has demonstrated extraordinary clinical results. It appears to have worked in 39 of 42 participants in a trial. Yet, inherent in the innovation of gene editing are unique challenges:

• Long-term safety and effectiveness: CRISPR’s long-term implications remain largely uncharted. Risk leaders must work with Pharmacovigilance colleagues to focus on robust post-market monitoring to identify potential long-term or off-target effects.
• Complex manufacturing and delivery processes: Personalized CRISPR therapies involve intricate cell-harvesting, editing, and transplantation processes. Ensuring consistent quality control, scalability, and secure custody throughout this delicate chain presents considerable operational and compliance risks.
• Ethical implications: Editing the human genome inherently raises significant ethical questions. Risk frameworks must address these considerations proactively, embedding ethical risk assessments into broader corporate responsibility mandates.

Navigating an evolving regulatory landscape

An evolving regulatory environment, particularly relevant in the US where there is potential for a relaxation of the FDA’s stringent standards, underscores the necessity for proactive regulatory engagement:

• Global compliance variability: Compliance teams must prepare for the complexities of navigating differing international regulatory requirements as CRISPR therapies become globalized.
• Data integrity and security: Handling patient genomic data and clinical trial records requires high standards of integrity and security to maintain patient confidentiality and regulatory compliance.
• Transparency and communication: Maintaining open and transparent communication with regulators, patients, and the broader public is crucial for sustaining trust and compliance.

Audit imperatives: Ensuring comprehensive oversight

Traditional audit methodologies must evolve to address CRISPR’s unique attributes. Critical audit focus areas might include:

• Process audits: Rigorous examination of end-to-end therapeutic processes is essential to uphold quality and safety standards.
• Data governance audits: Given the significant volume of genomic and clinical data generated, audits must verify data integrity, accuracy, and security.
• Vendor and partner audits: Collaborations with third party biotech firms and partners requires rigorous due diligence and continuous monitoring to assure compliance with stringent quality standards.

Preparing for the next wave of innovation: in vivo editing and beyond

The rapid development of in vivo CRISPR therapies, enabling gene editing directly within patients, brings additional opportunities, and challenges. New delivery methods, such as lipid nanoparticles, and advanced editing tools like base editing and prime editing, will introduce fresh complexities for risk management, compliance oversight, and audit scrutiny.

Embracing vigilance and proactivity

As we embrace this new CRISPR frontier, proactive vigilance is essential. Heads of Risk, Compliance, and Audit must cultivate agile frameworks capable of addressing the evolving scientific, operational, ethical, and regulatory demands of gene editing technologies. By staying ahead of the curve, industry leaders can confidently navigate this groundbreaking era, protecting patient safety, upholding ethical standards, and driving sustainable innovation forward.